Reaffirming Hold: Updated Earnings Outlook and Interest Assumptions Support Fair Valuation

Needham analyst David Saxon has maintained their neutral stance on XRAY stock, giving a Hold rating today.

David Saxon’s rating is based on management’s recent guidance regarding the pace of earnings per share growth into 2026, which prompted him to recalibrate his financial model. The company’s updated outlook did not, in his view, provide enough new upside to warrant a more bullish stance, but also did not deteriorate enough to justify a downgrade.

He also refined assumptions around interest expense, which modestly impacted projected profitability and reinforced a more balanced risk‑reward profile. Taken together, these adjustments suggest that the stock is fairly valued relative to its near‑term earnings trajectory, leading Saxon to reaffirm a Hold recommendation rather than moving to Buy or Sell.

In another report released today, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $11.50 price target.